Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials

BACKGROUND: Postoperative adjuvant cisplatin-based chemotherapy had been the standard care in patients with completely resected high-risk stage IB to IIIA non-small cell lung cancer (NSCLC) for decades. However, the survival benefits were far from satisfactory in clinical practice. Thus, this meta-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Pengfei, Zhen, Hongchao, Zhao, Hong, Zhao, Lei, Cao, Bangwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962534/
https://www.ncbi.nlm.nih.gov/pubmed/35346117
http://dx.doi.org/10.1186/s12885-022-09444-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962534/
https://www.ncbi.nlm.nih.gov/pubmed/35346117
http://dx.doi.org/10.1186/s12885-022-09444-0

Ejemplares similares